. 2022 Jul 23;135(12):1404–1413. doi: 10.1097/CM9.0000000000002217
Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
Figure 4.
Relevance of metastatic burden, metastatic sites with PFS. PFS: progression-free survival.